Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Front Neural Circuits ; 11: 93, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29218003

RESUMEN

Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are an important tool for modulating and understanding neural circuits. Depending on the DREADD system used, DREADD-targeted neurons can be activated or repressed in vivo following a dose of the DREADD agonist clozapine-N-oxide (CNO). Because DREADD experiments often involve behavioral assays, the method of CNO delivery is important. Currently, the most common delivery method is intraperitoneal (IP) injection. IP injection is both a fast and reliable technique, but it is painful and stressful particularly when many injections are required. We sought an alternative CNO delivery paradigm, which would retain the speed and reliability of IP injections without being as invasive. Here, we show that CNO can be effectively delivered topically via eye-drops. Eye-drops robustly activated DREADD-expressing neurons in the brain and peripheral tissues and does so at the same dosages as IP injection. Eye-drops provide an easier, less invasive and less stressful method for activating DREADDs in vivo.


Asunto(s)
Clozapina/análogos & derivados , Drogas de Diseño/administración & dosificación , Neuronas/efectos de los fármacos , Neurotransmisores/administración & dosificación , Soluciones Oftálmicas , Receptores de Neurotransmisores/metabolismo , Animales , Encéfalo/citología , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Clozapina/administración & dosificación , Dependovirus/genética , Femenino , Técnicas de Transferencia de Gen , Vectores Genéticos , Inyecciones Intraperitoneales , Masculino , Ratones de la Cepa 129 , Ratones Endogámicos C57BL , Neuronas/citología , Neuronas/metabolismo , Proteínas Proto-Oncogénicas c-fos/metabolismo , Pupila/efectos de los fármacos , Pupila/fisiología , Receptores de Neurotransmisores/administración & dosificación , Receptores de Neurotransmisores/genética
2.
Neurotoxicology ; 63: 43-56, 2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-28866071

RESUMEN

Soman (GD) exposure results in status epilepticus (SE) that leads to neurodegeneration, neuroinflammation, and behavioral consequences including learning and memory deficits. The neuroinflammatory response is characterized by the upregulation of the pro-inflammatory cytokine, interleukin-1 (IL-1), which mediates the expression of other neurotoxic cytokines induced after GD exposure. However, the specific role of IL-1 signaling has not been defined in terms of the consequences of GD-induced SE. Therefore, the purpose of this study was to regulate IL-1 signaling and study the behavioral deficits and neurodegeneration that occur after convulsion onset. Wild type (WT), IL-1 receptor (IL-1R1) knockout (KO), and IL-1 receptor antagonist (IL-1Ra) KO mice were exposed to a convulsive dose of GD, and behavior was evaluated up to 18days later. Activity was studied using the Open Field, anxiety was assessed in the Zero Maze, and spatial learning and memory were evaluated with the Barnes Maze. The animals were euthanized at 24hours and 18days to determine neuropathology in the piriform cortex, amygdala, thalamus, and CA1, CA2/3, and CA4 regions of the hippocampus. Unlike the IL-1Ra KO, the IL-1R1 KO showed less neuropathology compared to WT at 24hours, but moderate to severe injury was found in all strains at 18days. Compared to their saline controls, the exposed WT mice were significantly more active in the Open Field, and the IL-1R1 KO strain showed reduced anxiety in the Zero Maze Test. Compared to WT mice, IL-1R1 and IL-1Ra KO mice had spatial learning and memory impairments in the Barnes Maze. Therefore, the IL-1 signaling pathway affects neurodegeneration and behavior after GD-induced convulsions.


Asunto(s)
Encéfalo , Convulsivantes/toxicidad , Proteína Antagonista del Receptor de Interleucina 1/deficiencia , Receptores Tipo I de Interleucina-1/deficiencia , Soman/toxicidad , Estado Epiléptico , Animales , Encéfalo/diagnóstico por imagen , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Encéfalo/patología , Modelos Animales de Enfermedad , Conducta Exploratoria/efectos de los fármacos , Regulación de la Expresión Génica/efectos de los fármacos , Regulación de la Expresión Génica/genética , Proteína Antagonista del Receptor de Interleucina 1/genética , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Receptores Tipo I de Interleucina-1/genética , Transducción de Señal/efectos de los fármacos , Transducción de Señal/genética , Aprendizaje Espacial/efectos de los fármacos , Estado Epiléptico/inducido químicamente , Estado Epiléptico/genética , Estado Epiléptico/patología , Estado Epiléptico/fisiopatología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA